Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918472 | 0.84 | HTR2A (0.43) | PDE10ACNR1 | |
| SCHEMBL6919135 | 0.82 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL9607731 | 0.75 | PDE5A (0.45) | PDE10ACNR2CNR1HSD11B1 | |
| SCHEMBL4776578 | 0.72 | PDE10A (0.48) | PDE10A | |
| SCHEMBL6918499 | 0.69 | SMN1; SMN2 (0.36) | CNR2 | |
| SCHEMBL6917896 | 0.69 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL10570420 | 0.68 | PDE10A (0.41) | PDE10ATSHR | |
| SCHEMBL11197344 | 0.68 | CYP2D6 (0.50) | — | |
| SCHEMBL10570427 | 0.68 | PDE10A (0.41) | PDE10ATSHR | |
| SCHEMBL4421489 | 0.67 | PDE10A (0.83) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462123-B1 | 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| WO-2011017296-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | PDE10A 1073/4885CNR2 3332/4885CNR1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.